You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

LEMTRADA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: LEMTRADA
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for LEMTRADA
Recent Clinical Trials for LEMTRADA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
City of Hope Medical CenterPhase 1
M.D. Anderson Cancer CenterPhase 1
National Cancer Institute (NCI)Phase 1

See all LEMTRADA clinical trials

Pharmacology for LEMTRADA
Mechanism of ActionCD52-directed Antibody Interactions
Established Pharmacologic ClassCD52-directed Cytolytic Antibody
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LEMTRADA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LEMTRADA Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 ⤷  Try for Free 2013-08-13 Company disclosures
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 ⤷  Try for Free 2013-08-13 Company disclosures
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 ⤷  Try for Free 2014-08-05 Company disclosures
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 ⤷  Try for Free 2015-12-08 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for LEMTRADA Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for LEMTRADA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 32/2001 Austria ⤷  Try for Free PRODUCT NAME: ALEMTUZUMAB
132016000055697 Italy ⤷  Try for Free PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916
C20160019 00200 Estonia ⤷  Try for Free PRODUCT NAME: ALEMTUZUMAB;REG NO/DATE: EU/1/13/869 16.09.2013
132008901655480 Italy ⤷  Try for Free PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for LEMTRADA (Alemtuzumab)

Introduction

LEMTRADA (alemtuzumab) is a biologic drug developed by Sanofi and Genzyme, primarily used for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). This article delves into the market dynamics and financial trajectory of LEMTRADA, highlighting its clinical efficacy, market performance, and the impact of various factors on its sales.

Clinical Efficacy of LEMTRADA

LEMTRADA has demonstrated significant clinical efficacy in reducing relapses and slowing disability progression in patients with RRMS. In two 2-year clinical trials against Rebif (interferon beta-1a), LEMTRADA showed a lower annual relapse rate of 0.26 compared to 0.52 for Rebif. Additionally, 13% of patients who took LEMTRADA experienced confirmed disability progression, whereas 21% of those who took Rebif did so[1].

Market Approval and Collaboration

LEMTRADA is approved under different trade names for various conditions. Initially approved as Campath for the treatment of B-cell chronic lymphocytic leukemia (CLL), it was later optimized and rebranded as LEMTRADA for MS treatment. Sanofi and Genzyme collaborated with Bayer HealthCare for its co-promotion in the MS market[4].

Sales Performance

The sales of LEMTRADA have been influenced by several factors, including market competition, regulatory approvals, and global health crises.

Impact of COVID-19

The COVID-19 pandemic significantly impacted LEMTRADA sales, with a 60.3% decrease in the fourth quarter of 2020 and a 58.7% decrease for the full year 2020. This decline was largely attributed to the pandemic's disruption of healthcare services and patient access to treatments[5].

Geographic Sales

Sales forecasts and actual sales data indicate that LEMTRADA's performance varies across different regions. The drug has been forecasted to generate significant revenue in top markets such as the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. However, the actual sales have been affected by various regional factors, including competition and healthcare policies[4].

Financial Trajectory

Revenue Trends

Despite the initial promise, LEMTRADA's revenue has faced challenges. The drug's sales have not met the expected levels, partly due to the COVID-19 pandemic and intense competition in the MS treatment market. For instance, in 2020, the fourth-quarter and full-year sales of LEMTRADA were significantly lower than anticipated[5].

Business Operating Income

Sanofi's overall business operating income (BOI) has shown resilience, but the specific impact on LEMTRADA is less favorable. In 2020, Sanofi's BOI increased by 0.3% to €2,052 million, but this growth was not reflected in LEMTRADA's sales. The ratio of BOI to net sales increased, but this was more due to the performance of other products rather than LEMTRADA[5].

Competitive Landscape

The MS treatment market is highly competitive, with several drugs vying for market share. LEMTRADA competes with other biologics and disease-modifying therapies, which has impacted its sales. The competitive landscape includes drugs like Rebif, which LEMTRADA has been compared against in clinical trials, as well as newer entrants that may offer alternative treatment options[4].

Regulatory and Development Updates

LEMTRADA's development and regulatory status have been crucial for its market dynamics. The drug has undergone extensive clinical trials, and its efficacy has been established. However, regulatory approvals and market access have been influenced by various factors, including the withdrawal of Campath from the US and EU markets to focus on MS treatment[4].

Patient Outcomes and Long-Term Studies

Long-term studies have shown that patients treated with LEMTRADA have a higher likelihood of remaining relapse-free compared to those treated with Rebif. At the end of a 6-year study, 77% of patients who took LEMTRADA had stabilized or improved disability, indicating a positive long-term outcome[1].

Market Strategies and Future Outlook

Sanofi and Genzyme have employed several strategies to optimize LEMTRADA's market performance. These include focusing on R&D to enhance the drug's profile, managing expenses, and reinvesting savings into growth drivers. Despite current challenges, the companies remain committed to investing in R&D and leveraging AI to unlock the full potential of their pipeline, including LEMTRADA[3].

Conclusion

LEMTRADA's market dynamics and financial trajectory are complex and influenced by multiple factors. While the drug has shown significant clinical efficacy, its sales have been impacted by the COVID-19 pandemic, market competition, and regulatory considerations. As the biopharma landscape continues to evolve, Sanofi and Genzyme are focusing on R&D and strategic investments to improve LEMTRADA's market position.

Key Takeaways

  • Clinical Efficacy: LEMTRADA reduces relapses and slows disability progression in RRMS patients.
  • Market Impact: COVID-19 significantly reduced LEMTRADA sales in 2020.
  • Competitive Landscape: Intense competition in the MS treatment market affects LEMTRADA's sales.
  • Regulatory and Development: Ongoing R&D and regulatory approvals are crucial for LEMTRADA's market performance.
  • Long-Term Outcomes: Patients treated with LEMTRADA show better long-term disability outcomes.

FAQs

Q: What is LEMTRADA used for? A: LEMTRADA (alemtuzumab) is used for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS).

Q: How does LEMTRADA compare to Rebif in clinical trials? A: LEMTRADA showed a lower annual relapse rate and reduced disability progression compared to Rebif in clinical trials[1].

Q: What was the impact of the COVID-19 pandemic on LEMTRADA sales? A: The COVID-19 pandemic led to a significant decline in LEMTRADA sales, with a 60.3% decrease in the fourth quarter of 2020[5].

Q: Which regions are key markets for LEMTRADA? A: The key markets include the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India[4].

Q: What are the future outlook and strategies for LEMTRADA? A: Sanofi and Genzyme are focusing on R&D, expense management, and strategic investments to improve LEMTRADA's market performance and unlock its full potential[3].

Sources

  1. LEMTRADA® (alemtuzumab) Clinical Study Results - LEMTRADA.
  2. Press Release: Strong 2021 sales and business EPS growth - Sanofi.
  3. Press Release Q4 2023 English - Sanofi.
  4. Research and Markets: Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022 - Business Wire.
  5. Sanofi delivered close to double-digit Q4 2020 business EPS - Sanofi.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.